Bluejay Diagnostics (NASDAQ: BJDX) — Company Overview, News & Financial Data
Bluejay Diagnostics develops diagnostic testing solutions aimed at improving patient care and reducing healthcare costs.
Bluejay Diagnostics
Bluejay Diagnostics (NASDAQ:BJDX) is a healthcare company focused on developing and commercializing innovative diagnostic testing solutions aimed at improving patient care while reducing healthcare costs. Specializing in point-of-care tests, Bluejay is dedicated to addressing urgent clinical needs across various medical settings. One of their key projects includes the advancement of rapid, non-invasive testing platforms for conditions such as sepsis and other acute care conditions. Bluejay aims to make diagnostic testing more accessible and efficient, ultimately aiming to improve outcomes by enabling quicker decision-making in critical care situations.
Snapshot
Operations
Products and/or services of Bluejay Diagnostics
- Symphony IL-6 Test, a critical diagnostic tool for identifying sepsis and monitoring inflammation.
- Allereye Tear Total IgE Test, designed for diagnosing and managing allergic conjunctivitis.
- Point-of-care diagnostic platforms, enhancing rapid testing capabilities for various conditions.
- Biomarker discovery services, utilizing advanced technologies for identifying novel disease indicators.
- Custom assay development, tailored solutions for specific diagnostic needs.
- Research collaboration projects, partnering with institutions to advance diagnostic technologies and methodologies.
Bluejay Diagnostics executive team
- Indranil DeyPrincipal Financial, Accounting & Executive Officer, President, CEO and Director
- Kevin VanceChief Commercial Officer
- Mark W. FeinbergChief Medical Advisor
Latest news about Bluejay Diagnostics
Bluejay Diagnostics reports baseline 777-patient sepsis dataset
United StatesBluejay completes 750-patient sepsis study enrollment
United StatesBluejay Diagnostics surpasses 80% enrollment in pivotal sepsis triage trial
United StatesBluejay Diagnostics maps 2026 strategy for FDA submission of SYMON™ II trial
United StatesBluejay Diagnostics completes commercial-scale production of IL-6 antibodies
United States
Dividend history
Dividends per share paid by Bluejay Diagnostics, by financial year.
| Financial year | Interim | Final | Special | Total |
|---|---|---|---|---|
| FY2023 | — | — | — | $0.0975 |
Key financials
Reported results for Bluejay Diagnostics, in USD.
- Market cap
- 2.6M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -3.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -7M | -6.8M | |
| 0 | -7.2M | -7.7M | |
| 0 | -10.3M | -10M | |
| 249K | -9.3M | -9.3M |